Neil J O'Brien from Westminster, CA, age 65

Resumes

Project Manager

view source

Location:

Chino Hills, CA

Industry:

Construction

Neil O'brien

view source

Neil O'brien

view source

Neil O'brien

view source

Skills:

Microsoft Office

Neil O'brien

view source

Neil O'brien

view source

Location:

United States

Wikipedia References

Neil O'brien

Work:

It was praised by Michael Gove, then Shadow Secretary of State for Children, Schools and Families, and now Secretary of State for Education,
He has appeared on BBC Newsnight, Sky News and Channel Four news....

Education:

Area of science:

Radio • Housing

Specialty:

Director

Skills & Activities:

Sport:

Welfare

Us Patents

Mocetinostat In Combination With Chemotherapy To Treat Rhabdomyosarcoma
view source
US Patent:

20220280510, Sep 8, 2022
Filed:

Mar 7, 2022
Appl. No.:

17/688603
Inventors:

- Oakland CA, US
Noah FEDERMAN - Los Angeles CA, US
Dennis Joseph SLAMON - Woodland Hills CA, US
Neil O'BRIEN - Culver City CA, US
Assignee:

The Regents of the University of California - Oakland CA
International Classification:

A61K 31/506
A61K 31/395
A61P 35/00
A61K 9/00
Abstract:

The present disclosure provides a method of using mocetinostat in combination with vinorelbine to treating a patient with rhabdomyosarcoma (RMS). The patient can be a child, an adolescent, or an adult having a locally advanced RMS, an unresectable RMS, a metastatic RMS, or a recurrent RMS.

Kras G12C Inhibitors And Uses Thereof
view source
US Patent:

20220227738, Jul 21, 2022
Filed:

May 20, 2020
Appl. No.:

17/612972
Inventors:

- Pasadena CA, US
- Culver City CA, US
- Oakland CA, US
Brendan M. O'Boyle - Monrovia CA, US
Corey M. Reeves - Los Angeles CA, US
Oliver C. Loson - Monrovia CA, US
Brian M. Stoltz - San Marino CA, US
Martina S. McDermott - Los Angeles CA, US
Neil A. O'Brien - Los Angeles CA, US
Dennis Slamon - Los Angeles CA, US
International Classification:

C07D 403/14
C07D 471/10
C07D 487/10
C07D 491/10
C07D 495/10
C07D 498/10
Abstract:

The invention relates to compounds of Formula I, and pharmaceutically acceptable salts thereof, and methods of making and using the same. The compounds of the invention are effective in inhibiting KRAS protein with a G12C mutation and are suitable for use in methods of treating cancers mediated, in whole or in part, by KRAS G12C mutation.

Prmt5 Inhibitors And Uses Thereof
view source
US Patent:

20220194949, Jun 23, 2022
Filed:

Mar 25, 2020
Appl. No.:

17/598152
Inventors:

- Pasadena CA, US
- Culver City CA, US
- Oakland CA, US
Brian M. Stoltz - San Marino CA, US
Michael D. Bartberger - Sherman Oaks CA, US
Steven J. Wittenberger - Sherman Oaks CA, US
Oliver C. Loson - Monrovia CA, US
Martina S. McDermott - Los Angeles CA, US
Neil A. O'Brien - Los Angeles CA, US
Dennis Slamon - Los Angeles CA, US
International Classification:

C07D 487/04
A61P 35/00
Abstract:

The present disclosure describes compounds of formulas (I)-(V) and methods of making the same. The compounds of the present disclosure are useful as inhibitors of PRMT5 activity and in methods of treating cancers and other diseases.

Claudin-6 Bispecific Antibodies
view source
US Patent:

20220177583, Jun 9, 2022
Filed:

Mar 20, 2020
Appl. No.:

17/441183
Inventors:

- Los Angeles CA, US
Martina S. McDermott - Los Angeles CA, US
Neil A. O'Brien - Los Angeles CA, US
Michael J. Palazzolo - Los Angeles CA, US
Dennis Slamon - Los Angeles CA, US
Erika Von Euw - Los Angeles CA, US
Peter Bowers - Los Angeles CA, US
International Classification:

C07K 16/28
A61P 35/00
Abstract:

The present disclosure provides bispecific antigen-binding proteins which bind to Claudin-6 (CLDN6) and a second antigen. In various aspects, the antigen-binding proteins bind to Extracellular Loop 2 (EL2) of the extracellular domain of CLDN6. Related polypeptides, nucleic acids, vectors, host cells, and conjugates are further provided herein. Kits and pharmaceutical compositions comprising such entities are moreover provided. Also provided are methods of making an antigen-binding protein and methods of treating a subject having cancer.

Mcl1 Inhibitors And Uses Thereof
view source
US Patent:

20230116602, Apr 13, 2023
Filed:

Oct 2, 2020
Appl. No.:

17/766147
Inventors:

- Pasadena CA, US
- Culver City CA, US
- Oakland CA, US
Kevin C. Yang - San Gabriel CA, US
Tristin E. Rose - Los Angeles CA, US
Justin A. Hilf - Los Angeles CA, US
Brian M. Stoltz - San Marino CA, US
Michael D. Bartberger - Sherman Oaks CA, US
Oliver C. Loson - Monrovia CA, US
Martina S. McDermott - Los Angeles CA, US
Neil A. O'Brien - Los Angeles CA, US
Dennis Slamon - Woodland Hills CA, US
International Classification:

C07D 513/04
C07D 417/14
C07D 471/04
A61P 35/00
Abstract:

The present disclosure provides compounds, such as compounds of Formula I, and compositions that are MCL1 inhibitors.

Claudin-6 Antibodies And Drug Conjugates
view source
US Patent:

20230049752, Feb 16, 2023
Filed:

Jun 22, 2022
Appl. No.:

17/846900
Inventors:

- Oakland CA, US
Martina S. McDermott - Los Angeles CA, US
Neil A. O'Brien - Los Angeles CA, US
Michael J. Palazzolo - Los Angeles CA, US
Dennis Slamon - Los Angeles CA, US
Erika Von Euw - Los Angeles CA, US
Peter Bowers - Los Angeles CA, US
International Classification:

C07K 16/28
A61K 47/65
A61K 47/68
A61P 35/00
G01N 33/574
Abstract:

The present disclosure provides antigen-binding proteins which bind to Claudin-6 (CLDN6). In various aspects, the antigen-binding proteins bind to Extracellular Loop 2 (EL2) of the extracellular domain of CLDN6. Related polypeptides, nucleic acids, vectors, host cells, and conjugates are further provided herein. Kits and pharmaceutical compositions comprising such entities are moreover provided. Also provided are methods of making an antigen-binding protein and methods of treating a subject having cancer.